Shareholders to Vote on Doubling Authorized Shares and Expanding Equity Incentive Plan

summarizeSummary

Trevi Therapeutics is asking shareholders to approve a doubling of authorized common stock to 400 million shares and an 8 million share increase to its equity incentive plan, signaling significant future financing and compensation flexibility.

check_boxKey Events

• Proposed Increase in Authorized Common Stock

  Shareholders will vote on an amendment to increase the number of authorized common stock from 200,000,000 to 400,000,000 shares. This authorization provides significant headroom for future capital raises and strategic initiatives. If all authorized shares were issued, dilution would be approximately 155.5% based on current outstanding shares.

• Expansion of Equity Incentive Plan

  The company is seeking approval to add 8,000,000 shares to its Amended and Restated 2019 Stock Incentive Plan. These additional shares would be used for equity awards to employees, directors, and consultants, representing a potential dilution of approximately 6.23% of current outstanding shares.

• Annual Meeting Proposals

  The preliminary proxy statement outlines proposals for the 2026 Annual Meeting of Stockholders, including the election of one Class I director, ratification of Ernst & Young LLP as the independent auditor, and an advisory vote on executive compensation.

• Late Insider Trading Reports Noted

  The filing disclosed that certain entities affiliated with New Enterprise Associates filed late Form 5 reports in February 2026 to report warrant exercises from April 2025, due to administrative errors.

auto_awesomeAnalysis

Trevi Therapeutics is seeking shareholder approval to significantly increase its authorized common stock from 200 million to 400 million shares. This substantial increase provides the company with considerable flexibility for future capital raises, strategic transactions, and other corporate purposes without requiring additional shareholder votes. If all these newly authorized shares were issued, it would represent a potential dilution of approximately 155% to current outstanding shares. Additionally, the company proposes to add 8 million shares to its 2019 Stock Incentive Plan, which, if approved, would represent a potential dilution of about 6.23% to current outstanding shares for employee and director compensation. While these actions are necessary for a growing biotech company to fund operations and incentivize talent, the magnitude of potential future dilution is a significant consideration for existing shareholders.